Short answer: Mounjaro and Zepbound are the same medicine. Both are tirzepatide from Eli Lilly, in the same pens, vials and strengths (2.5 mg to 15 mg), injected once a week. The difference is what the FDA approved each one for. Mounjaro is for type 2 diabetes (and, since its latest label, lowering heart risk in adults with type 2 diabetes at high risk). Zepbound is for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. That one difference drives everything else: the dose goals, the trials behind each label, and usually what insurance will cover.
Below is a side-by-side of what the two FDA labels actually say, with section numbers so you can check each point yourself. Sources: the Zepbound label (DailyMed setid 487cd7e7, revised 08/2026) and the Mounjaro label (DailyMed setid d2d7da5d, current version published September 2026).
Same drug, same molecule
Both labels describe the active ingredient as tirzepatide, a GIP receptor and GLP-1 receptor agonist. Section 3 of each label lists identical dosage forms: single-dose pens and single-dose vials at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, plus multi-dose vials and KwikPens that each hold 4 weekly doses of 0.6 mL.
Because they are the same molecule, the Zepbound label says outright (section 1, Limitations of Use) that using it together with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended. In plain words: the label does not recommend taking both at once. If you are switching from one to the other, that is a conversation with your prescriber, not something to work out on your own.
What each one is approved for
Mounjaro (label section 1)
- Improving blood sugar control, alongside diet and exercise, in adults and children 10 years and older with type 2 diabetes.
- Reducing the risk of major heart events (heart-related death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.
Zepbound (label section 1)
- Reducing excess body weight and keeping it off long term, alongside a reduced-calorie diet and more physical activity, in adults with obesity, or adults with overweight who have at least one weight-related condition.
- Treating moderate to severe obstructive sleep apnea in adults with obesity.
Two practical points come out of this. First, Mounjaro has a pediatric approval for type 2 diabetes and Zepbound does not. Second, the reason someone is on one brand and not the other is usually the diagnosis on the prescription, not a difference in the drug.
Dosing schedule: what the labels say
This section reports what the FDA labels state. It is not dose advice. Your prescriber sets your dose.
Starting dose
Both labels start at 2.5 mg once a week. The Zepbound label (section 2.1) says the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose. The Mounjaro label (section 2.1) says the same escalation is meant to reduce the risk of stomach side effects.
Stepping up
Both labels raise the dose in 2.5 mg steps after at least 4 weeks on the current dose. The trigger is worded differently. Mounjaro steps up "if additional glycemic control is needed." Zepbound moves to 5 mg after 4 weeks, then may step up based on "treatment response and tolerability."
Maintenance and maximum
- Zepbound, weight: maintenance of 5, 10 or 15 mg weekly (section 2.2).
- Zepbound, sleep apnea: maintenance of 10 or 15 mg weekly (section 2.2).
- Mounjaro, adults: up to 15 mg weekly (section 2.1).
- Mounjaro, children 10 and older: up to 10 mg weekly (section 2.1).
The top dose for adults is 15 mg once a week on both labels.
Missed doses and changing your day
The rules are word for word the same. If you miss a dose, take it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take the next one on your normal day. You can move your weekly day as long as the two doses are at least 3 days (72 hours) apart (Zepbound section 2.3, Mounjaro section 2.1).
The trials behind each label
Zepbound: weight trials
Section 14.1 of the Zepbound label summarizes two 72-week trials. In Study 1 (SURMOUNT-1, 2,539 adults without diabetes; published by Jastreboff and colleagues, PubMed 35658024), average body weight changed by 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. In Study 2 (938 adults with type 2 diabetes), the change was 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo.
Notice the gap: people with type 2 diabetes lost less on average than people without it. That pattern is worth knowing if you are comparing your own numbers to headlines.
Mounjaro: blood sugar and heart trials
Mounjaro's label (section 14) is built on the SURPASS program, which measured HbA1c (a 3-month average of blood sugar). In SURPASS-1, 40 weeks of Mounjaro alone lowered HbA1c by 1.7 to 1.8 points from a starting average near 8.0%, against 0.1 on placebo. Weight also dropped, by 6.3 to 7.8 kg, but weight was a secondary measure. SURPASS-2 compared Mounjaro head to head with semaglutide 1 mg on top of metformin (Frías and colleagues, PubMed 34170647).
The newer heart indication comes from SURPASS-CVOT (label section 14.6), a trial in 13,299 adults with type 2 diabetes and established heart or blood vessel disease. It compared Mounjaro (up to 15 mg) with dulaglutide 1.5 mg, another weekly diabetes shot already approved to lower heart risk.
Side effects: same list, different numbers
The side effects are the same kinds on both labels, mostly stomach-related. The rates differ because the trials enrolled different people. From section 6.1:
- Zepbound weight trials: nausea in 25% to 29% of people (8% on placebo), diarrhea 19% to 23%, vomiting 8% to 13%, constipation 11% to 17%. Hair loss was reported in 4% to 5%.
- Mounjaro diabetes trials: nausea in 12% to 18% (4% on placebo), diarrhea 12% to 17%, decreased appetite 5% to 11%, vomiting 5% to 9%.
Both labels carry the same boxed warning about thyroid C-cell tumors seen in rats, and both list the same contraindications: a personal or family history of medullary thyroid carcinoma, MEN 2, or a known serious allergy to tirzepatide (section 4). Both also warn about pancreatitis, gallbladder problems, kidney injury from dehydration, serious stomach side effects, and low blood sugar when combined with insulin or sulfonylureas (section 5). Any side effect you have can be reported to your prescriber or to FDA MedWatch.
Storage and handling are identical
Section 16.2 of each label says the same thing. Keep pens and vials in the fridge at 36°F to 46°F (2°C to 8°C), in the original carton, away from light. Never freeze them, and do not use one that has frozen. If needed, a single-dose pen or single-dose vial can stay out of the fridge, at up to 86°F (30°C), for a total of 21 days. Multi-dose vials and KwikPens are thrown away after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first.
That matters this week: if you are driving to Thanksgiving dinner with a pen in your bag, the clock is the same 21 days for both brands. There is a fuller rundown in this Zepbound storage guide.
Why the price and coverage can differ
Insurance plans often cover diabetes drugs and weight drugs under different rules. Because Mounjaro is approved for type 2 diabetes and Zepbound for weight and sleep apnea, a plan may cover one and not the other even though the medicine is the same. Ask your plan which diagnosis it needs before assuming one brand is cheaper. Nothing in either FDA label changes based on price.
Quick comparison
- Active ingredient: tirzepatide in both.
- Approved for: Mounjaro, type 2 diabetes and heart risk in type 2 diabetes; Zepbound, weight and sleep apnea with obesity.
- Ages: Mounjaro adults and children 10+; Zepbound adults.
- Doses sold: same 2.5 to 15 mg pens and vials.
- Top adult dose: 15 mg weekly on both.
- Missed dose window: 4 days on both.
- Room temperature limit: 21 days for single-dose pens and vials on both.
- Use together: no; the Zepbound label says not to combine tirzepatide products or add a GLP-1 receptor agonist.
For a longer side-by-side, see Mounjaro vs Zepbound on Dose Track, or the Mounjaro overview.
Keeping track of your week
Whichever brand you are on, the things that cause the most trouble are the boring ones: forgetting which day you injected, losing count of how many days a pen has been out of the fridge, or not knowing whether a missed dose is still inside the 4-day window. Dose Track logs each shot with the time, keeps your weekly day, and tracks what is left in your pen or vial, so those answers are on your phone instead of in your head.
This article summarizes FDA labeling and published trials for general information. It is not medical advice. Talk to your prescriber before starting, stopping or switching any medicine.

